These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1709603)

  • 1. Recombinant human erythropoietin stimulates synthesis of fetal haemoglobin in haemodialysed patients with anaemia due to end-stage kidney.
    Hanicki Z; Sułowicz W; Stepniewski M; Kuźniewski M; Kraśniak A; Kopeć J; Cieszkowska U; Stolarska K
    Contrib Nephrol; 1990; 87():11-4. PubMed ID: 1709603
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recombinant human erythropoietin stimulates synthesis of fetal hemoglobin in patients with renal anemia treated by repeated hemodialysis].
    Hanicki Z; Sułowicz W; Stepniewski M; Kuźniewski M; Kraśniak A; Kopeć J; Cieszkowska U; Solarska K
    Pol Arch Med Wewn; 1991 Jun; 85(6):352-5. PubMed ID: 1716757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin.
    Sikole A; Efremov DG; Dimovski A; Efremov GD; Polenakovic M
    Nephron; 1993; 65(3):482-4. PubMed ID: 7507224
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietin treatment: influence of haemoglobin concentration on dialyser creatinine clearance in haemodialysed patients.
    Zehnder C
    Nephron; 1989; 51(3):424-5. PubMed ID: 2918959
    [No Abstract]   [Full Text] [Related]  

  • 6. Induction of fetal hemoglobin by recombinant human erythropoietin in patients with end-stage renal disease.
    Salvati F
    Nephron; 1993; 65(2):313. PubMed ID: 7504213
    [No Abstract]   [Full Text] [Related]  

  • 7. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?
    Sommerburg O; Grune T; Hampl H; Riedel E; van Kuijk FJ; Ehrich JH; Siems WG
    Nephrol Dial Transplant; 1998 Oct; 13(10):2583-7. PubMed ID: 9794564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.
    Marsden JT; Sherwood RA; Hillis A; Peters TJ
    Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():205-6. PubMed ID: 8466156
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.
    Winearls CG; Oliver DO; Pippard MJ; Reid C; Downing MR; Cotes PM
    Lancet; 1986 Nov; 2(8517):1175-8. PubMed ID: 2877323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of renal anemia with recombinant human erythropoietin].
    Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
    Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of erythropoietin on iron kinetics in patients with end-stage renal disease.
    Waters W; Wellner U; Baldamus CA; Bramsiepe P; Schicha H
    Contrib Nephrol; 1988; 66():156-64. PubMed ID: 3391030
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
    Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A
    Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?].
    Mesjasz J; Wiecek A; Gonciarz Z; Mazur W; Kokot F
    Pol Merkur Lekarski; 2004 Apr; 16(94):362-7. PubMed ID: 15517934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin stimulates F-reticulocyte formation in sickle cell anemia.
    al-Khatti A; Umemura T; Clow J; Abels RI; Vance J; Papayannopoulou T; Stamatoyannopoulos G
    Trans Assoc Am Physicians; 1988; 101():54-61. PubMed ID: 2480020
    [No Abstract]   [Full Text] [Related]  

  • 17. Resistance to recombinant human erythropoietin in a hemodialysis patient with lupus reactivation.
    Romero R; Novoa D; Perez-Freiria A; Arcocha V; Alonso R; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1995; 69(3):343-4. PubMed ID: 7753275
    [No Abstract]   [Full Text] [Related]  

  • 18. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease.
    Guerrero-Riscos MÁ; Montes-Delgado R; Seda-Guzmán M; Praena-Fernández JM
    Nefrologia; 2012 May; 32(3):343-52. PubMed ID: 22535158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum immunoreactive erythropoietin in patients with end stage renal disease.
    Gimenez LF; Watson AJ; Spivak JL
    Prog Clin Biol Res; 1990; 352():493-504. PubMed ID: 2402519
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.